Unfortunately, the tumor tissue available did not allow for us to include p-AKT as an additional parameter of interest to assess the compensatory feedback loop through the mTORC2-AKT pathway, following mTORC1 inhibition with everolimus [8]. Here, AKT1 is linked to neoplasm.